Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wilko Weichert

Showing results (381-390 of 504) with videos related to

Pageof 51
Sort By:
Theranostics|January 8, 2019
T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive targetKristine E Mayer, Sabine Mall, Nahid Yusufi, et al.
Cancers|March 6, 2021
Differential Effects of Trp53 Alterations in Murine Colorectal CancerAlexander M Betzler, Lahiri K Nanduri, Barbara Hissa, et al.
European Urology|April 8, 2023
Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic EvolutionAlexander Cox, Niklas Klümper, Johannes Stein, et al.
British Journal of Cancer|November 7, 2019
Post-neoadjuvant cellular dissociation grading based on tumour budding and cell nest size is associated with therapy response and survival in oesophageal squamous cell carcinomaMoritz Jesinghaus, Melanie Boxberg, Dirk Wilhelm, et al.
Der Pathologe|May 27, 2021
[MSI testing : What is new? What should be considered? German version]Josef Rüschoff, Gustavo Baretton, Hendrik Bläker, et al.
Theranostics|October 4, 2018
Simultaneous characterization of tumor cellularity and the Warburg effect with PET, MRI and hyperpolarized <sup>13</sup>C-MRSIChristian Hundshammer, Miriam Braeuer, Christoph A Müller, et al.
Cancer Letters|December 19, 2015
Phenotypic differentiation does not affect tumorigenicity of primary human colon cancer initiating cellsTaronish D Dubash, Christopher M Hoffmann, Felix Oppel, et al.
Der Pathologe|September 3, 2021
MSI testing : What's new? What should be considered?Josef Rüschoff, Gustavo Baretton, Hendrik Bläker, et al.
Nature Communications|July 21, 2020
Proteome activity landscapes of tumor cell lines determine drug responsesMartin Frejno, Chen Meng, Benjamin Ruprecht, et al.
Oncotarget|March 31, 2018
A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomyMarkus Eckstein, Ralph M Wirtz, Carolin Pfannstil, et al.
Pageof 51

Showing results (381-390 of 504) with videos related to

Sort By:
Pageof 51
Theranostics|January 8, 2019
T-cell functionality testing is highly relevant to developing novel immuno-tracers monitoring T cells in the context of immunotherapies and revealed CD7 as an attractive targetKristine E Mayer, Sabine Mall, Nahid Yusufi, et al.
Cancers|March 6, 2021
Differential Effects of Trp53 Alterations in Murine Colorectal CancerAlexander M Betzler, Lahiri K Nanduri, Barbara Hissa, et al.
European Urology|April 8, 2023
Molecular Urothelial Tumor Cell Subtypes Remain Stable During Metastatic EvolutionAlexander Cox, Niklas Klümper, Johannes Stein, et al.
British Journal of Cancer|November 7, 2019
Post-neoadjuvant cellular dissociation grading based on tumour budding and cell nest size is associated with therapy response and survival in oesophageal squamous cell carcinomaMoritz Jesinghaus, Melanie Boxberg, Dirk Wilhelm, et al.
Der Pathologe|May 27, 2021
[MSI testing : What is new? What should be considered? German version]Josef Rüschoff, Gustavo Baretton, Hendrik Bläker, et al.
Theranostics|October 4, 2018
Simultaneous characterization of tumor cellularity and the Warburg effect with PET, MRI and hyperpolarized <sup>13</sup>C-MRSIChristian Hundshammer, Miriam Braeuer, Christoph A Müller, et al.
Cancer Letters|December 19, 2015
Phenotypic differentiation does not affect tumorigenicity of primary human colon cancer initiating cellsTaronish D Dubash, Christopher M Hoffmann, Felix Oppel, et al.
Der Pathologe|September 3, 2021
MSI testing : What's new? What should be considered?Josef Rüschoff, Gustavo Baretton, Hendrik Bläker, et al.
Nature Communications|July 21, 2020
Proteome activity landscapes of tumor cell lines determine drug responsesMartin Frejno, Chen Meng, Benjamin Ruprecht, et al.
Oncotarget|March 31, 2018
A multicenter round robin test of PD-L1 expression assessment in urothelial bladder cancer by immunohistochemistry and RT-qPCR with emphasis on prognosis prediction after radical cystectomyMarkus Eckstein, Ralph M Wirtz, Carolin Pfannstil, et al.
Pageof 51